Printer Friendly

Excaliard Pharmaceuticals Inc reports improved data from Phase 2 clinical trial of EXC 001 for skin scarring.

M2 EQUITYBITES-4 August 2010-Excaliard Pharmaceuticals Inc reports improved data from Phase 2 clinical trial of EXC 001 for skin scarring(C)2010 M2 COMMUNICATIONS http://www.m2.com

Biotechnology company Excaliard Pharmaceuticals Inc said on Tuesday that the company has received positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis, in the randomised, double-blind multicentre study conducted in the US.

According to the company, the results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.

The company claimed that the final analysis for this study will be conducted 24 weeks after surgery and the data will be available in the second half of 2010.

EXC 001 was reportedly co-discovered by Isis Pharmaceuticals Inc (Nasdaq:ISIS) and Excaliard and licensed to Excaliard Pharmaceuticals.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 4, 2010
Words:151
Previous Article:Watson Pharmaceuticals names Robert Stewart as executive vice president, global operations.
Next Article:RBC Life Sciences posts 16% raise in second quarter sales.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters